1 Amgen, Inc., Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, California.
2 Amgen, Inc., Discovery Attribute Sciences, Amgen Research, Thousand Oaks, California.
Nucleic Acid Ther. 2019 Jun;29(3):161-166. doi: 10.1089/nat.2018.0770. Epub 2019 Mar 12.
The potential repertoire of short interfering RNA (siRNA) therapeutics is expanding as targeting strategies evolve. One approach to enable organ-specific delivery has been to directly conjugate siRNA to a monoclonal antibody (siRNA-mAb), analogous to antibody-drug conjugates. Detection of intact siRNA-mAb conjugates presents a bioanalytical challenge given that certain synthetic nucleotide chemical modifications and low-temperature requirements render common oligonucleotide detection assays, such as reverse transcription-polymerase chain reaction, incompatible with the immunoassay component. To circumvent these issues, we developed a triplex-forming oligonucleotide ELISA using locked nucleic acid (LNA) containing oligonucleotide probes. We demonstrate that the incorporation of these LNAs allow for an enrichment and immobilization of siRNA directly conjugated to an antibody at nondenaturing temperatures. Without further requirement for extraction or amplification, we can sensitively and specifically detect intact siRNA-mAb conjugates in complex matrices such as serum and tissue homogenate.
作为靶向策略不断发展的结果,短干扰 RNA (siRNA) 治疗药物的潜在库正在扩大。一种实现器官特异性递送的方法是将 siRNA 直接缀合到单克隆抗体 (siRNA-mAb) 上,类似于抗体-药物偶联物。鉴于某些合成核苷酸化学修饰和低温要求使得常见的寡核苷酸检测测定(例如逆转录-聚合酶链反应)与免疫测定组件不兼容,因此检测完整的 siRNA-mAb 缀合物具有生物分析挑战性。为了规避这些问题,我们使用含有锁核酸 (LNA) 的寡核苷酸探针开发了一种三聚体形成寡核苷酸 ELISA。我们证明,这些 LNA 的掺入允许在非变性温度下直接将与抗体缀合的 siRNA 进行富集和固定。无需进一步提取或扩增,我们就可以在复杂基质(如血清和组织匀浆)中灵敏且特异性地检测完整的 siRNA-mAb 缀合物。